Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of the optimal third generation antifolate against P. falciparum and P. vivax.

Molecular and biochemical parasitology - 1 Dec 2005

Hunt Sonia Y, Detering Carsten, Varani Gabriele, Jacobus David P, Schiehser Guy A, Shieh Hong-Ming, Nevchas Isabelle, Terpinski Jacek, Sibley Carol Hopkins

Abstract excerpt

Inhibitors of dihydrofolate reductase (DHFR) have been mainstays in the treatment of falciparum malaria. Resistance to one of these antifolates, pyrimethamine, is now common in Plasmodium falciparum populations. Antifolates have not traditionally been recommended for treatment of vivax malaria. However, recent studies have suggested that a third-generation antifolate, WR99210, is remarkably effective even against...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Design
Share to Folic Acid Antagonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitory Concentration 50

Share to Molecular Conformation

Share to Plasmodium falciparum

Share to Plasmodium vivax

Share to Tetrahydrofolate Dehydrogenase

Share to Triazines

Source

Identifiers

PMID: 16181688
DOI: 10.1016/j.molbiopara.2005.08.014

Genes

DHFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of the optimal third generation antifolate against P. falciparum and P. vivax.PMID 16181688Read ↗

Exploiting Structural Analysis, <i>in Silico</i> Screening, and Serendipity To Identify Novel Inhibitors of Drug-Resistant Falciparum MalariaSemantic proximity Read ↗

Mutagenesis of dihydrofolate reductase from Plasmodium falciparum: analysis in Saccharomyces cerevisiae of triple mutant alleles resistant to pyrimethamine or WR99210.Semantic proximity Read ↗

Evaluation of the activities of pyrimethamine analogs against Plasmodium vivax and Plasmodium falciparum dihydrofolate reductase-thymidylate synthase using in vitro enzyme inhibition and bacterial complementation assays.Semantic proximity Read ↗

Isomerization of antimalarial drug WR99210 explains its inactivity in a commercial stockSemantic proximity Read ↗

Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised targetSemantic proximity Read ↗

In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase.Semantic proximity Read ↗

Dihydrofolate Reductase as a Target for Chemotherapy in ParasitesSemantic proximity Read ↗

Mutational 'hot-spots' in mammalian, bacterial and protozoal dihydrofolate reductases associated with antifolate resistance: sequence and structural comparison.Semantic proximity Read ↗

In Vitro Efficacy of Next Generation Dihydrotriazines and Biguanides Against Babesiosis and Malaria ParasitesSemantic proximity Read ↗

Novel alleles of the Plasmodium falciparum dhfr highly resistant to pyrimethamine and chlorcycloguanil, but not WR99210.Semantic proximity Read ↗

Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall ResistanceSemantic proximity Read ↗

Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.